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Abstract
Epithelial-mesenchymal-transition (EMT) is a fundamental cellular process that is critical for normal development and tumor
metastasis. The transforming growth factor beta (TGFb) is a potent inducer of EMT like effects, but the mechanisms that
regulate TGFb-induced EMT remain incompletely understood. Using the widely employed NMuMG mammary epithelial cells
as a model to study TGFb-induced EMT, we report that TGFb downregulates the levels of the SUMO E3 ligase PIAS1 in cells
undergoing EMT. Gain and loss of function analyses indicate that PIAS1 acts in a SUMO ligase dependent manner to
suppress the ability of TGFb to induce EMT in these cells. We also find that TGFb inhibits sumoylation of the PIAS1 substrate
SnoN, a transcriptional regulator that antagonizes TGFb-induced EMT. Accordingly, loss of function mutations of SnoN
sumoylation impair the ability of SnoN to inhibit TGFb-induced EMT in NMuMG cells. Collectively, our findings suggest that
PIAS1 is a novel negative regulator of EMT and reveal that inhibition of the PIAS1-SnoN sumoylation pathway represents a
key mechanism by which TGFb induces EMT, with important implications in normal development and tumor metastasis.
Citation: Netherton SJ, Bonni S (2010) Suppression of TGFb-Induced Epithelial-Mesenchymal Transition Like Phenotype by a PIAS1 Regulated Sumoylation
Pathway in NMuMG Epithelial Cells. PLoS ONE 5(11): e13971. doi:10.1371/journal.pone.0013971
Editor: Marc Vooijs, University Medical Center Maastricht, Netherlands
Received April 6, 2010; Accepted October 19, 2010; Published November 12, 2010
Copyright:  2010 Netherton, Bonni. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work is supported by grants from the Alberta Cancer Board (ACB), and the Canadian Institutes of Health Research to SB. SJN is an ACB Postdoctoral
Fellow. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sbonni@ucalgary.ca
Introduction
Epithelial-mesenchymal transition (EMT) is a fundamental
biological process that is critical for proper tissue and organ
morphogenesis in the developing organism [1]. EMT also is
important for wound healing [1]. EMT is reactivated in pathological
conditions including fibrotic and neoplastic diseases, and importantly
EMT contributes to tumor metastasis [1,2,3,4]. Epithelial cells are
characterized by apical-basal polarity that is maintained by
specialized junctions including the apical tight junctions and
basolateral adherens junctions as well as by an organized cytoskeletal
architecture. Thus, EMT induces a morphological alteration in
epithelial cells from an apical-basal polarized to a spindle-like non-
polarized phenotype. EMT comprises the loss of epithelial cell
polarity and cell-cell adhesion due to changes in cytoskeletal
architecture and cell junctional proteins [2,3,5,6]. Consistent with
these morphological alterations, cells undergoing EMT show a
change in the actin cytoskeleton from cortical F-actin type to stress
fiber-like. EMT also induces downregulation or mislocalization of the
epithelial marker and adherens junctional protein E-cadherin [7]. E-
cadherin exerts a central role in epithelial homeostasis and its loss at
the cell-cell junctions leads to reduced expression and/or organiza-
tion of other epithelial markers including zona occludins-1 [8].
Reduction in E-cadherin levels at the sites of cell-cell attachments is
considered to be a hallmark of EMT [9,10,11]. In addition,
downregulation of E-cadherin is a predictive marker of invasiveness
and metastatic potential of many forms of cancer, including breast
and gastric tumors [12,13,14,15].
The transforming growth factor beta (TGFb) family of proteins
plays pleiotropic and essential roles in normal development and
homeostasis [16,17]. A key function of TGFb is its ability to induce
EMT [1,5,6,18]. TGFb-induced EMT plays critical roles in
development and wound healing, and contributes to the ability of
TGFb to promote tumor progression observed at later stages of
many malignancies including mammary, prostate, and colorectal
carcinomas [5,19,20,21,22].
TGFb initiates signaling in responsive cells by forming an
activated heteromeric complex with specific transmembrane
TGFb type I and II serine/threonine kinase receptors
[23,24,25,26]. The type II receptor kinase phosphorylates and
activates the type I receptor, which in turn induces the activation
of the canonical intracellular Smad signaling pathway
[27,28,29,30,31]. The Smad proteins, which are transcription
factors, are required for the ability of TGFb to induce EMT. In
particular, the Smad proteins induce the expression of other
transcription factors, including Snail and Zeb1, that are thought to
repress the expression of the E-cadherin gene [22]. Although the
mechanisms that mediate TGFb induction of EMT are beginning
to be elucidated, how the function of TGFb in EMT is regulated
has remained unexplored.
PIAS1 [protein inhibitor of activated STAT (signal transducer
and activator of transcription) 1] was originally identified based on
its ability to interact with and inhibit STAT1 binding to DNA
[32,33]. Later studies showed that PIAS1 is a SUMO E3 ligase
[34,35,36]. Sumoylation involves the covalent attachment of the
protein SUMO (small ubiquitin like modifier) to e-amino group in
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the sequential action of three sets of enzymes [37]. In the first step,
an E1 enzyme covalently binds a SUMO molecule in an ATP-
dependent fashion. The SUMO molecule is transferred next to the
SUMO E2 conjugating enzyme Ubc9. A SUMO E3 ligase binds
to Ubc9 and specific substrates, and thereby facilitates the transfer
of a SUMO molecule from Ubc9 to specific lysine residues within
substrates. As a SUMO E3 ligase, PIAS1 enhances the sumoyla-
tion of transcriptional regulators, including the transcriptional
modulator SnoN, which plays a critical role in TGFb responses
[38,39]. However, the functional significance of PIAS1 in TGFb-
induced EMT induction has remained unknown.
In this study, we uncover a novel mechanism that regulates
EMT. We show that TGFb reduces the level of the SUMO E3
ligase PIAS1 in cells undergoing EMT. Loss and gain of function
experiments suggest that PIAS1 antagonizes EMT. We also find
that TGFb leads to inhibition of sumoylation of the PIAS1
substrate SnoN during EMT. Loss of function experiments
demonstrate that sumoylation contributes to the ability of SnoN
to inhibit EMT. Thus, our study identifies the SUMO E3 ligase
PIAS1 as a novel regulator of TGFb-induced EMT.
Results
TGFb downregulates the SUMO ligase PIAS1 during EMT
To identify novel regulators of EMT, we employed mouse
mammary epithelial NMuMG cells, widely used for studies of
EMT [40,41,42]. We first confirmed that TGFb induced EMT in
these cells. NMuMG cells that were untreated or incubated for 2
days with TGFb in the absence or presence of TGFb type I
receptor kinase (TbRI) inhibitor SB431542 were assessed for EMT
[43,44]. A key molecular hallmark of EMT is loss or mislocaliza-
tion of the epithelial cell-cell junction protein E-cadherin. We used
an indirect immunofluorescence approach to visualize the
localization and quantify the levels of E-cadherin using the
Cellomics Kinetic Scan Reader (KSR) and associated Spot-
Detector bioapplication [45]. TGFb led to marked reduction of E-
cadherin in NMuMG cells, and the TbRI inhibitor completely
blocked this effect of TGFb (Figures 1A and 1B). We also
monitored actin reorganization from cortical to stress fiber type
and cell shape change from cuboidal to fibroblastic like, as
additional alterations associated with EMT. We used fluorescently
labeled phalloidin and the whole cell dye stain CMFDA to
visualize changes in actin reorganization and cell shape,
respectively. TGFb stimulation triggered actin stress fiber
formation and fibroblastic phenotype that were blocked by TbRI
inhibitor (Figures S1A and S1B). Collectively, these data confirm
that TGFb induces EMT in these cells.
Next, we used a candidate approach to identify potential novel
regulators of TGFb-induced EMT. The SUMO E3 ligase PIAS1
can regulate TGFb signaling but the potential role of PIAS1 in
EMT remained unidentified. To determine the role of PIAS1 in
TGFb-induced EMT, we first measured the levels of PIAS1 in
NMuMG cells that were left untreated or that were incubated with
TGFb for 2 days. Surprisingly, we found that TGFb dramatically
reduced the levels of PIAS1 in NMuMG cells (Figure 1C). The
TbRI inhibitor blocked the ability of TGFb to decrease the level of
PIAS1 as well as that of the epithelial marker E-cadherin
(Figure 1D). We confirmed that TbRI inhibitor blocked TGFb-
induced phosphorylation of Smad2 (Figure 1D). Next, we
determined if the decrease in the levels of PIAS1 in cells
undergoing EMT was at the level of transcription. However,
TGFb had little or no effect on the levels of PIAS1 mRNA
(Figure 1E). We then considered the possibility that TGFb-
dependent reduction in the levels of PIAS1 might be due to an
increase in PIAS1 ubiquitination and consequent degradation. To
test this idea, we incubated control and TGFb-treated NMuMG
cells with the proteasome inhibitor MG132 to protect polyubi-
quitinated proteins from proteasomal degradation. We found that
TGFb induced the polyubiquitination of PIAS1 in NMuMG cells
(Figure 1F). These data suggest that TGFb reduces the level of
PIAS1 via the ubiquitin-proteasome pathway in cells undergoing
EMT.
PIAS1 is a member of the PIAS family of SUMO E3 ligases that
also includes PIAS2, PIAS3, and PIAS4 [46]. We therefore also
determined effect of TGFb on the levels of PIAS 2, 3 and 4
mRNA and protein in NMuMG cells (see Materials and Methods
S1). We found that PIAS2, PIAS3 and PIAS4 mRNAs were
expressed in control NMuMG cells as determined by RT-PCR
analyses, and their levels were not altered upon TGFb treatment
(Figure S1C). Immunoblotting analyses revealed that PIAS3 and
PIAS4 were expressed in NMuMG cells but there was little or no
expression of PIAS2 in these cells (Figure S1D). In contrast to
TGFb-induced downregulation of PIAS1 protein in NMuMG
cells (Figure 1C), TGFb did not appreciably alter the levels of the
PIAS3 and PIAS4 proteins (Figure S1D). Together, these data
suggest that TGFb may selectively induce the downregulation of
PIAS1 among the PIAS proteins.
PIAS1 acts in a SUMO ligase dependent manner to inhibit
EMT
The finding that TGFb reduces the level of PIAS1 in cells
undergoing EMT led us to characterize the function of PIAS1 in
EMT. We first tested the effect of expression of exogenous PIAS1
on an E-cadherin promoter driven luciferase reporter gene, whose
repression represents a reliable readout of EMT [47,48]. We
confirmed that TGFb suppressed expression of the E-cadherin
luciferase reporter gene in NMuMG cells (Figures 2Ai and 2Aii).
Expression of exogenous PIAS1 inhibited the ability of TGFb to
repress the E-cadherin reporter without affecting the basal level of
the E-cadherin reporter in NMuMG cells (Figure 2Ai). The
cysteine-rich RING type zinc finger domain in PIAS1 is required
for its interaction with the E2 SUMO conjugating Ubc9 and
hence for the E3 SUMO ligase activity of PIAS1 [35]. We tested
the effect of expression of a mutant PIAS1 protein, in which
Cysteine 350 within the zinc finger domain was converted to
serine, on the E-cadherin-luciferase reporter gene [38]. We
confirmed that the wild type and the SUMO ligase mutant PIAS1
were expressed at equivalent levels (see Materials and Methods S1;
Figures S2Ai and S2Aii). Importantly, we found that the SUMO
ligase mutant PIAS1 failed to antagonize TGFb-inhibition of the
E-cadherin reporter gene (Figures 2Ai and 2Aii). We next carried
out a dose-response study to further confirm the role and
specificity of the SUMO ligase activity in the ability of PIAS1 to
inhibit TGFb repression of the E-cadherin promoter. These data
showed that PIAS1 antagonized TGFb-induced suppression of the
E-cadherin reporter gene in a dose-dependent manner (Figure 2B).
In contrast, the SUMO E3 ligase mutant PIAS1 (CS) did not block
the ability of TGFb to inhibit the E-cadherin reporter at any
concentration (Figure 2B). Collectively, these data suggest that the
SUMO ligase activity is critical for PIAS1 to block TGFb-
repression of E-cadherin transcription.
To characterize the role of endogenous PIAS1 on the ability of
TGFb to downregulate E-cadherin transcription, we employed an
RNAi approach to induce knockdown of PIAS1 ([38] and Figures
S2Bi and S2Bii). Expression of PIAS1 short hairpin RNAs
enhanced the ability of TGFb to suppress the E-cadherin
promoter suggesting that endogenous PIAS1 counteracts TGFb-
PIAS1 Negatively Regulates EMT
PLoS ONE | www.plosone.org 2 November 2010 | Volume 5 | Issue 11 | e13971Figure 1. TGFb downregulates the SUMO E3 ligase PIAS1 in cells undergoing EMT. A) E-cadherin immunofluorescence images of NMuMG
cells, left untreated (2 TGFb), or incubated with TGFb (+ TGFb), the TGFb-receptor type I kinase (TbRI) inhibitor SB431542 (+ KI), alone or together for
48 h. B) Each column is the mean (6 SEM, n=3 experiments) of percent suppression of cellular E-cadherin by TGFb relative to that of the basal for
each of 2KI and +KI (see MATERIALS and METHODS). TGFb induces EMT as indicated by nearly 90% reduction in the level of the epithelial marker E-
cadherin in cells. The KI blocks TGFb reduction of E-cadherin and hence induction of EMT. C) TGFb decreases endogenous PIAS1 levels in NMuMG
cells undergoing EMT. Lysates of NMuMG cells left untreated or incubated with TGFb (48 h) were subjected to PIAS1 (a-PIAS1) and actin (a-actin)
immunoblotting (IB). D) TbRI-signaling is required for downregulation of PIAS1. Lysates of NMuMG cells left untreated or incubated with TGFb (48 h),
KI (for 48 h or for the last 24 h), alone or together, were subjected to PIAS1, E-cadherin (a-E-cadherin), Smad2 (a-Smad2) and phospho-Smad2 (a-
pSmad2) immunoblotting. TGFb increases phospho-Smad2 while reducing the levels of PIAS1 and E-cadherin. The KI blocks the ability of TGFb to
downregulate PIAS1 and E-cadherin. E) TGFb does not reduce the levels of PIAS1 mRNA. RT-PCR of RNA extracts from NMuMG cells incubated
without or with TGFb for 48 h to analyze mRNA levels of PIAS1 and the internal control GAPDH (see MATERIALS and METHODS). F) TGFb enhances
endogenous PIAS1 ubiquitination in NMuMG cells. Lysates of cells treated with the proteasome inhibitor MG132 (last 24 h of a 48 h culture), TGFb
PIAS1 Negatively Regulates EMT
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(Figure 2C). Collectively, these data suggest that the SUMO E3
PIAS1 inhibits TGFb-repression of E-cadherin expression.
We next used biochemical and cell-based approaches to test the
possibility that PIAS1 negatively regulates TGFb-induced EMT.
We first generated NMuMG cells that stably expressed the wild
type or SUMO ligase mutant PIAS1, or that were stably
transfected with the control vector. Immunoblotting analyses
confirmed that the wild type and SUMO E3 ligase mutant PIAS1
were expressed at equivalent level in these cells (Figure 3A).
Comparison of the level of exogenous PIAS1 in these cells relative
to control transfectants showed that expression of the wild type or
SUMO E3 ligase mutant PIAS1 was only modestly increased
relative to endogenous levels of PIAS1 (Figure 3A). Immunoblot-
ting analyses using an antibody to E-cadherin revealed that
expression of PIAS1 decreased the ability of TGFb to suppress the
levels of E-cadherin protein in NMuMG cells (Figure 3B).
Quantitative analysis confirmed that the ability of PIAS1 to
reverse TGFb downregulation of E-cadherin levels was statistically
significant (Figure 3C). In contrast, we found that mutation of the
SUMO ligase activity significantly mitigated the ability of PIAS1
to inhibit TGFb-repression of E-cadherin protein level (Figures 3B
and 3C). Together, these data show that PIAS1 protects E-
cadherin protein from TGFb-dependent downregulation.
We also examined the effect of PIAS1 expression on different
EMT parameters using cell-based assays. At the basal epithelial
state, expression of PIAS1 did not appreciably affect the
localization or expression of E-cadherin (Figure 3D). Similarly,
we found that wild type or SUMO ligase mutant PIAS1 did not
alter significantly the cortical actin organization or cuboidal cell
shape in untreated cells (Figures S3A and S3B). In contrast,
expression of wild type but not the SUMO ligase mutant PIAS1
drastically inhibited the ability of two different concentrations of
TGFb to induce a loss in E-cadherin levels (Figures 3D and 3E).
Expression of PIAS1 suppressed the ability of TGFb to induce the
formation of actin stress fibers and fibroblastic cell phenotype
(Figures S3A and S3B). In contrast, the SUMO ligase mutant
PIAS1 did not reduce the ability of TGFb to change actin
reorganization and cell shape (Figures S3A and S3B). Collectively,
these findings suggest that the SUMO E3 ligase activity of PIAS1
plays a critical role in suppressing the ability of TGFb to induce
EMT.
The PIAS1 substrate SnoN contributes to PIAS1 inhibition
of EMT
The finding that the SUMO E3 ligase activity is required for the
ability of PIAS1 to antagonize EMT suggested that specific
SUMO substrates might mediate the effect of PIAS1 on this
fundamental cellular process. The transcriptional regulator SnoN
plays important roles in TGFb signaling and responses, including
antagonizing TGFb-induced EMT in cancer cells [39,49].
Recently, we and others showed that SnoN is sumoylated and
that Lysines 50 and 383 on SnoN are major sites for SUMO
conjugation [38,50]. We also identified SnoN as a PIAS1 SUMO
substrate [38,50]. We therefore tested the hypothesis that
sumoylation contributes to the ability of SnoN to inhibit TGFb-
induced EMT and that TGFb triggers a reduction in the levels of
PIAS1 and hence sumoylated SnoN to mediate EMT. SUMO-
conjugated proteins can be difficult to detect due to their
desumoylation by SUMO-proteases that might be activated
during lysis [37,51]. The general SUMO-protease inhibitor N-
ethylmaleimide (NEM) is typically included in the lysis buffer to
preserve the SUMO-conjugated species in the cellular extracts
[52,53]. Using SDS-PAGE analysis, the apparent molecular mass
of these NEM-sensitive SUMO-conjugated species is 20 kDa or
more as compared to the unmodified protein [37,54]. We
prepared NMuMG cellular extracts in the absence or presence
of NEM and subjected these lysates to SnoN immunoprecipitation
followed by SnoN immunoblotting. We first confirmed that
endogenous SnoN was sumoylated in NMuMG cells as indicated
by the appearance of several specific slow migrating NEM-
sensitive SnoN immunoreactive species as compared to unmod-
ified SnoN in SnoN immunoprecipitates (Figure 4A). Next, we
examined the status of SnoN sumoylation in cells undergoing
EMT. Interestingly, we found that TGFb stimulation led to a
reduction in the proportion of NEM-sensitive sumoylated-SnoN
species in cells undergoing EMT (Figure 4B). In other experi-
ments, inhibition of TbRI blocked the ability of TGFb to reduce
sumoylated-SnoN in these cells (Figure 4C). These data suggest
that TGFb signaling reduces the level of SnoN sumoylation in cells
undergoing EMT.
The finding that TGFb decreases SnoN sumoylation suggested
that this modification may contribute to SnoN’s ability to inhibit
EMT. To test this possibility, we compared the effect of stable
expression of wild type SnoN or a SUMO loss of function SnoN
mutant, in which Lysines 50 and 383 were converted to arginine
residues (SnoN (KdR)), on EMT [38]. Wild type and mutant
SnoN were expressed at equivalent levels (Figure 5A). Upon
immunoblotting, we found that wild type SnoN inhibited the
ability of TGFb to suppress E-cadherin expression (Figures 5B and
5C). In contrast, expression of the SUMO loss of function SnoN
mutant (KdR) had little or no effect on the ability of TGFb to
reduce E-cadherin expression (Figures 5B and 5C). Likewise,
expression of wild type SnoN but not SnoN (KdR) antagonized
TGFb-inhibition of E-cadherin in the NMuMG cells as deter-
mined by immunocytochemistry (Figures 5D and 5E). These data
suggest that sumoylation may be important for SnoN to inhibit
TGFb-induced EMT.
In addition to sumoylation, lysine residues can undergo other
modifications including acetylation and methylation [37,55]. To
exclude the possibility that the lack of effect of the SnoN (KdR) on
E-cadherin suppression by TGFb is due to impairment of potential
modifications other than sumoylation, we generated a distinct
SUMO loss of function SnoN mutant (SnoN (EdA)) in which
Glutamates 52 and 385 within SUMO consensus motifs (yKXE)
in SnoN were converted to alanine residues (Figure 6A). The
acidic amino acid in position +3 of the SUMO consensus motif is
critical for covalent linkage of the lysine residue with SUMO [37].
Accordingly, we found that replacement of Glutamates 52 and 383
with alanines abrogated the ability of SnoN to undergo
sumoylation at Lysines 50 and 383 (Figure 6B).
We next compared the effect of stable expression of wild type
and the SUMO loss of function SnoN (EdA) on EMT. Wild type
SnoN and the SnoN (EdA) mutant were expressed at comparable
levels in these cells (Figure 6C). Immunoblotting analyses showed
that while wild type SnoN blocked the ability of TGFb to reduce
E-cadherin expression, the SnoN (EdA) mutant was ineffective in
counteracting the TGFb response (Figures 6D and 6E). Likewise,
immunofluorescence studies showed that although wild type SnoN
blocked downregulation of E-cadherin in NMuMG cells under-
(48 h), alone or together were subjected to PIAS1 immunoprecipitation followed by sequential ubiquitin and PIAS1 immunoblotting. Scans in C to F
are representative of experiments that were carried out at least 3 independent times.
doi:10.1371/journal.pone.0013971.g001
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inhibit the TGFb response (Figures 6F and 6G). Collectively, our
findings suggest that sumoylation contributes significantly to the
ability of SnoN to inhibit TGFb-reduction of E-cadherin and
hence induction of EMT. In turn, TGFb decreases the level of
sumoylated SnoN to facilitate EMT.
Figure 2. PIAS1 inhibits the ability of TGFbto suppress E-cadherin promoter activity. A) PIAS1 decreases TGFb inhibition of E-cadherin
promoter activity in a SUMO E3 ligase-dependent manner. Lysates of NMuMG cells transfected with the E-cadherin promoter driven luciferase (E-
cadherin-p-luciferase) reporter and the b-galactosidase (b-gal) expression construct together with an empty expression vector (2), or one encoding
wild type PIAS1 (WT) or SUMO E3 ligase mutant PIAS1 (CS), and left untreated or incubated with 100 pM TGFb for 48 h, were subjected to luciferase
and b-galactosidase assays (see MATERIALS and METHODS). Ai) Each column is the mean (6 SEM, n=5) of b-galactosidase normalized luciferase data
relative to that of the basal (2 TGFb) vector control. Aii) Each column is the mean (6 SEM, n=5) of the percent repression of luciferase activity by
TGFb relative to that of the basal (2 TGFb) of the corresponding transfection as shown in Ai (see MATERIALS and METHODS). B) PIAS1 reversal of
TGFb-inhibition of the E-cadherin promoter activity is dose-dependent. Lysates of untreated or TGFb-treated cells transfected with E-cadherin-p-
luciferase reporter and b-gal plasmid together with an empty vector or increasing concentrations of plasmids containing PIAS1 (WT) or PIAS1 (CS)
were subjected to luciferase and b-galactosidase assays. Each column is the mean (6 SEM, n=6) of percent suppression of E-cadherin luciferase
activity by TGFb. C) Endogenous PIAS1 knockdown enhances TGFb suppression of E-cadherin reporter expression. Lysates of untreated or TGFb
treated NMuMG cells transiently transfected with the E-cadherin-p-luciferase reporter and b-gal construct together with a control vector (control) or
one encoding short hairpin RNAs to knockdown endogenous PIAS1 (PIAS1i), were subjected to luciferase and b-galactosidase assays. Each column is
the mean (6 SEM, n=6) of percent suppression of E-cadherin luciferase activity by TGFb from six independent experiments. * indicates statistical
significant difference (P,0.05) as compared to the corresponding TGFb treatment vector control.
doi:10.1371/journal.pone.0013971.g002
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PLoS ONE | www.plosone.org 6 November 2010 | Volume 5 | Issue 11 | e13971The finding that sumoylation contributes to SnoN’s ability to
inhibit TGFb-induced EMT supports the conclusion that SnoN
mediates the ability of the SnoN SUMO E3 ligase PIAS1 to
suppress EMT. To further investigate the role of PIAS1-SnoN
sumoylation pathway in the regulation of EMT, we examined the
codependence of PIAS1 and SnoN in inhibiting TGFb-induced
downregulation of E-cadherin promoter. First, we asked whether
expression of the SUMO loss of function SnoN (EdA) mutant
might act in a dominantly interfering manner to block the function
of the SUMO E3 ligase PIAS1 in NMuMG cells. Co-
immunoprecipitation studies revealed that the SnoN (EdA) mutant
was as effective as the wild type SnoN in associating with PIAS1
(Figure 7A). Importantly, in reporter analysis assays, we found that
expression of the SnoN (EdA) mutant, but not the wild type SnoN,
blocked the ability of PIAS1 to mitigate TGFb repression of E-
cadherin-promoter activity (Figure 7B). Quantitative immunoflu-
orescence analysis showed that PIAS1 was expressed at similar
levels in the control NMuMG cells as well as cells expressing wild
type SnoN or the SnoN (EdA) mutant (Figures S4Ai and S4Aii). In
other experiments, we examined the effect of expression of the
SUMO E3 ligase inactive PIAS1 (CS) mutant on the ability of
exogenous SnoN to block TGFb-repression of E-cadherin
promoter transcription. Co-immunoprecipitation experiments
demonstrated that SnoN interacts with PIAS1 (CS) as effectively
as with wild type PIAS1 (Figure 7C). In reporter assays, we found
that expression of the PIAS1 (CS) mutant, but not the wild type
PIAS1, reversed the ability of SnoN to counter TGFb-repression
of E-cadherin transcription (Figure 7D). Immunofluorescence
analysis showed that SnoN was expressed at similar levels in
control NMuMG cells as well as those expressing wild type PIAS1
or the PIAS1 (CS) mutant (Figures S4Bi and S4Bii). Together,
these findings support the conclusion that SnoN plays a critical
role in the ability of PIAS1 to block TGFb-repression of E-
cadherin promoter activity during EMT. Collectively, our findings
point to an important functional link involving TGFb, PIAS1 and
SnoN in the regulation of EMT.
Discussion
In this report, we identify a novel mechanism that regulates
EMT. We have found that TGFb reduces the levels of the SUMO
E3 ligase PIAS1 in cells undergoing EMT. Expression of PIAS1
antagonizes the ability of TGFb to induce EMT. Importantly, the
SUMO E3 ligase activity of PIAS1 is critical for its suppression of
EMT. TGFb stimulation leads to the inhibition of sumoylation of
the PIAS1 substrate SnoN. Loss of function mutations of SnoN
sumoylation abrogated the ability of SnoN to inhibit TGFb-
induced EMT. Collectively, these data suggest that PIAS1-induced
sumoylation of SnoN antagonizes EMT. Conversely, TGFb leads
to a reduction in the level of PIAS1 and sumoylated SnoN to
facilitate the induction of EMT.
The identification of PIAS1 downregulation as a critical
mechanism for TGFb-induced EMT bears significant implications
for our understanding of TGFb responses. Since EMT comprises
the loss of apical-basal polarity and cell-cell adhesion of epithelial
cells, PIAS1 inhibition of EMT suggests that PIAS1 may play a
critical role in maintaining cell polarity and cell-cell contact in
epithelial tissues. In other words, the PIAS1 sumoylation pathway
may operate as a checkpoint that must be overcome by TGFb
signaling in order for EMT to proceed. In future studies, it will be
important to determine the role of PIAS1 activity in organizing the
morphogenesis of epithelial tissues during development and in the
control of metastasis of epithelial tumors. Because TGFb regulates
a diverse set of biological responses including cell proliferation,
differentiation and apoptosis, our findings suggest that PIAS1 may
also influence other TGFb-regulated responses in addition to
EMT.
PIAS1 interacts with a number of proteins including transcrip-
tional regulators and signal transducers, many of which have been
identified as PIAS1 SUMO substrates [46]. The finding that
TGFb triggers the downregulation of PIAS1 in cells undergoing
EMT uncovers a novel mechanism that modulates PIAS1 actions.
The increase in polyubiquitinated PIAS1 conjugates in cells
undergoing EMT suggests that TGFb signaling may lead to
alteration in the expression or activity of components of the
ubiquitin machinery that ultimately may regulate PIAS1 in these
cells. It will be important in future studies to identify the ubiquitin
ligases or deubiquitinases that may couple TGFb signaling to the
control of PIAS1 ubiquitination and consequent degradation.
An important question raised by our study is how PIAS1-
induced sumoylation promotes the ability of SnoN to antagonize
TGFb-induced EMT. Sumoylation impacts the subcellular
localization, stability, or transcriptional activity of protein
substrates. However, sumoylation does not appear to affect the
stability or subcellular localization of SnoN [38]. Therefore, it will
be important in future studies to determine the molecular basis
underlying the ability of sumoylation of SnoN to inhibit EMT.
In summary, our study defines an important and novel role for
the SUMO E3 ligase PIAS1 as a suppressor of EMT. In particular,
our data indicate that SnoN, a PIAS1 SUMO ligase substrate,
might contribute to the ability of PIAS1 to inhibit EMT. On the
other hand, TGFb inhibits the PIAS1-SnoN sumoylation pathway
in cells undergoing EMT. As EMT is critical for proper
development and in the progression of cancer, it will be important
in future studies to identify the role of PIAS1 and sumoylated
SnoN in these biological processes.
Figure 3. PIAS1 suppresses the loss of E-cadherin levels associated with TGFb-induced EMT. A) Expression of wild type and the SUMO
ligase mutant (CS) PIAS1 in stable NMuMG cells. Lysates of NMuMG cells stably transfected with the control vector expressing the resistance marker
alone or together with wild type (WT) or SUMO E3 ligase mutant (CS) PIAS1 were subjected to anti-FLAG immunoprecipitation (a-FLAG IP) followed
by anti-PIAS1 immunoblotting (upper panel), or were immunoblotted for PIAS1 and actin, the latter to serve as loading control (lower two panels).
Wild type and SUMO ligase mutant PIAS1 (CS) are expressed at similar levels. B and C) PIAS1 acts in a SUMO E3 ligase dependent manner to suppress
TGFb-reduction in E-cadherin protein level. B) Lysates of NMuMG cells stably transfected with the control plasmid or a plasmid encoding WT or CS
PIAS1 as in A and left untreated or incubated with TGFb for 48 h were subjected to E-cadherin and actin immunoblotting. Scans are from a
representative experiment that was repeated 4 times. C) Each column is the mean (6 SEM, n=4) of percent reduction by TGFb of actin-normalized E-
cadherin levels relative to the basal levels of the respective transfectant obtained from immunoblots including those shown in B (see MATERIALS and
METHODS). D) Representative E-cadherin immunofluorescence images of vector control (2), wild type (WT) or SUMO E3 ligase mutant (CS) PIAS1
expressing NMuMG stable cells that were left untreated (I) or incubated with 20 pM (II) or 100 pM (III) TGFb for 48 h. E) Quantification of E-cadherin
immunofluorescence from images as shown in D. Intensity of E-cadherin immunofluorescence per cell was obtained and analyzed (see MATERIALS
and METHODS). Each column is the mean (6 SEM, n=4) of percent reduction in E-cadherin levels by 20 pM (clear column) or 100 pM (grey column)
TGFb. * indicates statistical significant difference (p,0.05) as compared to the vector control.
doi:10.1371/journal.pone.0013971.g003
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Ethics Statement
N/A
Plasmids
CMV-based plasmids to express FLAG-tagged wild type SnoN
(WT), SUMO loss of function SnoN where Lysines 50 and 383
were converted to arginine residues (KdR), wild type PIAS1 (WT),
and SUMO E3 ligase mutant PIAS1 where Cysteine 350 was
converted to serine (CS) have been described previously [35,38].
FLAG-tagged SUMO loss of function SnoN (EdA) in which
Glutamates 52 and 385 were changed to alanines was generated
by a PCR-based approach. The pCAGiP/FLAG expression
vector containing cDNA encoding PIAS1 (WT or CS), or SnoN
(WT, KdR, or EdA) protein was generated by subcloning the
respective cDNA into the pCAGIP vector as described elsewhere
[45,56]. A pCAGiP vector enables the coexpression of the gene
product of interest and the puromycin resistance marker from an
internal ribosomal entry site (IRES) containing bicistronic
transcript. The PIAS1 RNA interference vector encoding PIAS1
short hairpin RNAs and enhanced green fluorescent protein (GFP)
under the control of the U6 and CMV promoters, respectively,
was described previously [38,57]. The E-cadherin-p-luciferase
reporter, a generous gift from Dr. A. Cano, and the internal
control b-galactosidase reporter constructs have been previously
described [45,47,57]. The plasmids were confirmed by restriction
digests and/or DNA sequence analyses (University of Calgary
Core Sequencing Facility).
Cell Cultures and Transfections
The NAMRU mouse mammary gland epithelial cells
(NMuMG) were purchased from American Type Culture
Collection (ATCC) and cultured in Dulbecco’s modified Eagle’s
medium (Invitrogen) with high glucose and L-glutamine, supple-
mented with 10 mg/mL insulin and 10% fetal bovine serum
(Invitrogen). The human kidney epithelial (293T) cells [58,59]
were maintained in Dulbecco’s modified Eagle’s medium
(Invitrogen) with high glucose and L-glutamine, supplemented
with 10% fetal bovine serum. NMuMG cells at approximately
70% confluency were incubated in regular media in the absence or
presence of TGFb and left at 37uC for 48 h to induce EMT. The
TGFb receptor type I kinase (TbRI) inhibitor, SB431542 (Sigma),
was used at 10 mM, where indicated. 293T cells were transiently
transfected using the calcium phosphate method. NMuMG cells
were transiently transfected using FuGENE 6 (Roche Applied
Science) or TransIT LT1 (Mirus) according to the manufacturer’s
instructions. Pools of NMuMG stables expressing a puromycin-
resistant marker alone or together with PIAS1 or SnoN were
obtained by transfecting cells with pCAGIP-based vectors
containing specific cDNA using Lipofectin (Invitrogen) according
to the manufacturer’s instructions, followed by selection of
resistant cells using 2 mg/ml puromycin (Invitrogen).
Reporter Assays
NMuMG cells were seeded in 24-well plates at approximately
4.5610
4 cells/well one day prior to transfections. Cells were co-
transfected with the E-cadherin-promoter-driven firefly luciferase
reporter and the CMV-b-galactosidase internal control reporter
constructs, together with a control expression vector or one
encoding wild type PIAS1 (WT), SUMO ligase mutant PIAS1
(CS), or the PIAS1 RNAi plasmid (PIAS1i), as outlined in the
figure legends. 18 h post transfection, cells were incubated in fresh
media in the absence or presence of 100 pM TGFb, and left for an
additional 48 h, to allow for the induction of EMT where
applicable. Lysates were prepared and analyzed for luciferase
activity using a commercially available firefly luciferase assay kit
[38,45,57]. Arbitrary luciferase activity (relative light units) values
were normalized to b-galactosidase activity to account for
variations in transfection efficiency. For each transfection, percent
repression by TGFb of E-cadherin promoter driven luciferase
reporter gene expression was also determined and expressed
relative to luciferase activity of the respective basal condition
lysates (2TGFb). Each experimental condition was carried out in
Figure 4. TGFb inhibits SnoN sumoylation in cells undergoing
EMT. A) Endogenous SnoN is sumoylated in NMuMG cells. NMuMG cell
extracts prepared in the absence (2) or presence (+) of the isopeptidase
inhibitor N-ethylmaleimide (NEM) were subjected to anti-SnoN or
control IgG immunoprecipitation followed by SnoN immunoblotting.
Several NEM-sensitive slow migrating SnoN-immunoreactive species as
compared to unmodified SnoN were identified (SUMO-SnoN). B) TGFb
reduces SnoN sumoylation in cells undergoing EMT. Cells were left
untreated or incubated with TGFb for 48 h to induce EMT. NEM-
containing lysates were analyzed as described in A. C) Inhibition of TbRI-
dependent signaling blocks downregulation of SnoN sumoylation by
TGFb. NEM-treated lysates of NMuMG cells left untreated, or incubated
with TGFb alone or together with the TbRI inhibitor (KI) were subjected
to SnoN immunoprecipitation followed by SnoN immunoblotting as
described in A. Each of the scans in A, B and C is a representative blot
from an experiment that was repeated two to three times.
doi:10.1371/journal.pone.0013971.g004
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five to six independent experiments.
Reverse Transcription-PCR
NMuMG cells were lysed using TRIzol lysis reagent (Invitro-
gen), followed by total RNA extraction and concentration using
chloroform and isopropanol/ethanol, respectively. The reverse
transcriptase SuperScript II (Invitrogen) and oligo(dT)12–18
(Amersham Biosciences) as the primer were used to generate
Poly(A)-cDNA as described before [38,45,57]. Mouse PIAS1
(1080 bp) and GAPDH (300 bp) cDNA fragments were PCR-
amplified using the mouse poly(A)-cDNA as a template and gene
specific PIAS1 (sense 59-GGTATACGGGAAAAACCGG-39;
antisense 59- TCAGAGGTTACGAGCAAAGG-39), and
GAPDH (sense 59-CGGAGTCAACGGATTTGGTCGTAT-39;
antisense 59-AGCCTTCTC CATGGTGGTGAAGAC-39) oligo-
nucleotides as primers. The PCR products were resolved and
stained using 1.2% agarose gels and ethidium bromide, respec-
tively. The amplified cDNA products were scanned and visualized
using the VersaDoc 5000 Imager (Bio-Rad).
Immunoprecipitation and Immunoblotting
NMuMG or 293T cell extracts prepared in TNTE (50 mM
Tris-HCl, pH 7.4, 150 mM NaCl and 1 mM EDTA) buffer
containing 0.5% Triton X-100 with protease and phosphatase
inhibitors were centrifuged at 14,000 x g for 10 min at 4uCa s
described previously [38,45,57]. 20 mM N-ethylmaleimide (NEM;
Sigma), an isopeptidase inhibitor, was included in the lysis buffer
where indicated [38]. Supernatants’ protein compositions were
resolved by SDS-PAGE followed by western blotting using
antibodies to proteins of interest. In experiments investigating
PIAS1 ubiquitination or SnoN sumoylation, the majority of the
supernatant was also subjected to immunoprecipitation using goat
anti-PIAS1 (N-18; Santa Cruz), or rabbit anti-SnoN (H317; Santa
Cruz) antibodies, respectively [38]. In studies examining the
association of SnoN and PIAS1, a large fraction of the supernatant
was subjected to immunoprecipitation using mouse anti-FLAG
(M2; Sigma) or anti-MYC (9E10; Covance). Immunoprecipita-
tions were performed on equivalent amounts of total protein in
each sample. The protein contents of total cell lysate and
immunoprecipitation samples were resolved by SDS-PAGE
followed by immunoblotting using rabbit anti-SnoN, rabbit-anti
ubiquitin (FL-76; Santa Cruz), mouse anti-E-cadherin (BD
Transduction Laboratories), rabbit anti-PIAS1 (Epitomics), mouse
anti-Smad2/3 (BD, Transduction Laboratories), rabbit anti-
phospho Smad2 (Calbiochem), mouse anti-FLAG, mouse anti-
MYC, and rabbit anti-actin (Sigma) as primary antibodies and
horseradish peroxidase-conjugated anti-mouse or anti-rabbit
antibody (Amersham Biosciences) as the secondary antibodies
[57]. ECL (Amersham Biosciences)-generated signals were visual-
ized and quantified using a VersaDoc 5000 Imager and Quantity
One software (Bio-Rad), respectively.
In experiments investigating the effect of expression of wild type
PIAS1, SUMO E3 ligase mutant PIAS1 (CS), wild type SnoN, or
SUMO loss of function SnoN mutants on the ability of TGFb to
inhibit E-cadherin protein expression, the densities of E-cadherin
and actin immunoblots in the absence and presence of TGFb were
quantified from appropriate scans including those shown in
Figures 3B, 5B, and 6D, and E-cadherin levels were normalized
to the corresponding actin levels. For each transfectant, reduction
of actin-normalized E-cadherin protein levels by TGFb was
determined and expressed as a percent of actin-normalized E-
cadherin levels in the respective basal (TGFb-untreated) lysates.
Each column in the bar graph shown in each of Figures 3C, 5C
and 6E represents the mean (6 SEM) of percent suppression of E-
cadherin protein levels by TGFb of a transfectant from several
independent experiments as indicated by the n value in
parenthesis in the respective figure legend.
Immunocytochemistry and Fluorescence-Cell Based
Analyses
1610
4 NMuMG cells were seeded per well in 96-well plates and
incubated without or with TGFb for 48 h to induce EMT. Cells
were fixed with 4% formaldehyde, permeabilized with 0.2%
Triton-X100, and blocked using 5% BSA and 5% calf serum in
phosphate buffered saline (PBS) [45]. Subcellular localization and
levels of E-cadherin were determined by incubating cells with a
mouse anti-E-cadherin antibody followed by Cy3-conjugated anti-
mouse IgG using a well established indirect immunofluorescence
protocol [45]. For whole cell imaging, live cells were stained with 5
mM 5-chloromethylfluorescein diacetate (CMFDA) (Molecular
Probes), according to manufactures instructions, followed by fixing
as described above. For actin staining, fixed cells were incubated
with TRITC-conjugated phalloidin (Sigma). All cells were
incubated with the DNA fluorescent dye Hoechst 33342
(Invitrogen) to visualize their nuclei (data not shown). Images
were acquired using the Cellomics Kinetic Scan Reader that is
equipped with Carl Zeiss Axiom x microscope and a charge-
coupled device (CCD) digital camera [45]. Representative E-
cadherin immunofluorescence images are shown in Figures 1A,
3D, 5D, and 6F. Each micrograph corresponds to a 350 mm width.
The SpotDetector bioapplication was used to quantify E-cadherin
fluorescence intensity per cell, with cells identified by nuclear stain,
from images including those shown in Figures 1A, 3D, 5D, and 6F.
Each condition was carried out at least in triplicates per
experiment, i.e. at least three wells of a 96-well plate, and the
immunofluorescence data were averaged from a minimum of 2000
cells per well. For each condition, the reduction of E-cadherin
immunofluorescence intensity by TGFb was expressed as a
percent of the E-cadherin immunofluorescence level in the
Figure 5. SnoN sumoylation contributes to the ability of SnoN to antagonize TGFb-suppression of E-cadherin. A) Wild type SnoN and
the SUMO loss of function SnoN (SnoN (KdR)) are expressed at equivalent levels in NMuMG stable cells. Lysates of NMuMG cells stably transfected
with the control vector expressing the resistance marker alone or together with wild type SnoN (WT) or SUMO loss of function SnoN (KdR) were
subjected to FLAG immunoprecipitation followed by SnoN immunoblotting (upper panel), or were immunoblotted for SnoN and actin, the latter
serving as a loading control (lower two panels). B and C) Wild type but not the SUMO loss of function SnoN inhibits TGFb-reduction in E-cadherin
protein level in cells undergoing EMT. B) Representative scans of E-cadherin and actin immunoblots of lysates of control vector, wild type SnoN (WT)
or SUMO loss of function SnoN (KdR) expressing cells that were left untreated or incubated with TGFb. C) The densities of E-cadherin and actin
immunoblots as shown in Figure 5B were analyzed (see MATERIALS and METHODS). Each column in the bar graph represents the mean (6 SEM,
n=4) of percent suppression of E-cadherin protein level by TGFb. D) Representative micrographs of E-cadherin-indirect immunofluorescence of
vector control (2), wild type (WT) or SUMO loss of function (KdR) SnoN expressing NMuMG cells that were left untreated (I) or incubated with 20 pM
(II) or 100 pM (III) TGFb for 48 h. E) Intensity of E-cadherin immunofluorescence per cell was obtained and analyzed (see MATERIALS and METHODS).
Each column in the bar graph represents the mean (6 SEM, n=3) of percent reduction in E-cadherin levels by 20 pM (clear column) or 100 pM (grey
column) TGFb. * indicates statistical significant difference (p,0.05) as compared to the vector control.
doi:10.1371/journal.pone.0013971.g005
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graph in Figures 1B, 3E, 5E, and 6G represents the mean (6
SEM) of percent suppression of E-cadherin immunofluorescence
intensity by TGFb of a transfectant from several independent
experiments as indicated by the n value in parenthesis in the
respective figure legend.
Figure 7. The PIAS1-SnoN sumoylation pathway antagonizes TGFb-suppression of E-cadherin promoter activity. A) SUMO loss of
function SnoN associates with PIAS1. Lysates of 293T cells expressing PIAS1, SnoN (WT) or SUMO loss of function SnoN (EdA) mutant, alone or
together were subjected to SnoN immunoprecipitation (a-FLAG IP) followed by sequential PIAS1 (a-MYC) and SnoN (a-SnoN) immunoblotting.
Expression of PIAS1, SnoN, and actin in lysates were confirmed by MYC, SnoN, and actin immunoblotting. B) The SUMO loss of function SnoN mutant
inhibits PIAS1 to block TGFb-reduction of E-cadherin transcription. NMuMG cells stably expressing SnoN (WT) or SnoN (EdA) or stably transfected with
the vector control plasmid (2) were transiently transfected with the E-cadherin-p-luciferase reporter and the b-gal plasmid together with an empty
expression vector (2) or one encoding the PIAS1 protein (+) were subjected to luciferase and b-galactosidase assays (see MATERIALS and METHODS).
Each column is the mean (6 SEM, n= 6) of percent reduction of E-cadherin-p-luciferase activity by TGFb. C) The SUMO ligase mutant PIAS1 interacts
with SnoN. Lysates of 293T cells expressing SnoN, PIAS1 (WT) or SUMO E3 ligase mutant PIAS1 (CS), alone or together were subjected to PIAS1
immunoprecipitation (a-MYC IP) followed by SnoN (a-SnoN) and PIAS1 (a-MYC) immunoblotting. Total lysates were immunoblotted as described in
7A. D) SUMO E3 ligase mutant PIAS1 reverses the effect of SnoN to inhibit TGFb-repression of E-cadherin promoter activity. NMuMG cells stably
expressing PIAS1 (WT) or PIAS1 (CS), or stably transfected with the vector control plasmid (2) were transiently transfected with the E-cadherin-p-
luciferase reporter and the b-gal plasmid together with an empty expression vector (2) or one encoding the SnoN protein (+) were subjected to
luciferase and b-galactosidase assays. Data from 6 independent experiments are presented as outlined in Figure 7B. * indicates statistical significant
difference (P,0.05) as compared to vector control (column one of each B and D).
doi:10.1371/journal.pone.0013971.g007
Figure 6. Sumoylation mediates the ability of SnoN to antagonize TGFb-suppression of E-cadherin expression. A) A schematic
showing the two SUMO consensus motifs in SnoN and the amino acid residues that are mutated in each of the SnoN (KdR) and SnoN (EdA). B)
Glutamates 52 and 385 are critical for SnoN to be sumoylated on Lysines 50 and 383. NEM-treated lystaes of 293T cells expressing HA-tagged SUMO1,
alone or together with SnoN (WT), SnoN (EdA) or SnoN (KdR) were subjected to FLAG immunoprecipitation followed by sequential HA (a-HA) and
SnoN immunoblotting. Representative scans from an experiment that was done 4 times. C) Equivalent expression of SnoN (WT) and the SnoN (EdA) in
NMuMG stable cells. Lysates of cells stably transfected with the control vector, SnoN (WT) or SUMO loss of function SnoN (EdA) were subjected to
FLAG immunoprecipitation followed by SnoN immunoblotting, or were immunoblotted for SnoN and actin. D and E) SnoN (WT) but not SnoN (EdA)
inhibits TGFb-reduction in E-cadherin protein level in cells undergoing EMT. D) Scans of E-cadherin and actin immunoblots of lysates of control
vector, SnoN (WT) or SnoN (EdA) expressing cells that were left untreated or incubated with TGFb as in Figure 3B. E) Each column is the mean (6 SEM,
n=5) of percent suppression of E-cadherin protein by TGFb obtained by analysis of immunoblots including those shown in 6D (see MATERIALS and
METHODS). F) Representative images of E-cadherin immunofluorescence of vector control (2), SnoN (WT) or SnoN (EdA) expressing NMuMG cells that
were left untreated (I) or incubated with TGFb (II and III) as in Figure 3D. G) Each column is the mean (6 SEM, n=5) of percent reduction in E-cadherin
levels by 20 pM (clear column) or 100 pM (grey column) TGFb from images as shown in 6F (see MATERIALS and METHODS). * indicates statistical
significant difference (p,0.05) as compared to the vector control.
doi:10.1371/journal.pone.0013971.g006
PIAS1 Negatively Regulates EMT
PLoS ONE | www.plosone.org 12 November 2010 | Volume 5 | Issue 11 | e13971Statistical Analysis
Mean values of independent experiments repeated at least three
times were subjected to student-t-test or analysis of variance
(ANOVA) followed by post hoc tests to determine statistical
significance (p,0.05).
Supporting Information
Materials and Methods S1
Found at: doi:10.1371/journal.pone.0013971.s001 (0.03 MB
DOC)
Figure S1 Analysis of TGFb-induced EMT and assessment of
changes in levels of PIAS members by TGFb. A and B) Analysis of
TGFb-induced EMT in NMuMG cells A) NMuMG cells left
untreated, or incubated with TGFb, the TbRI inhibitor SB431542
(KI), alone or together for 48 h were fixed and subjected to actin
staining with TRITC-conjugated phalloidin. B) Cells treated as in
A were incubated with the CMFDA whole cell fluorescent dye
then fixed. Cells in A and B were also co-stained with the Hoechst
DNA fluorescent dye (data not shown). Cells were scanned using
the Cellomics KSR at X20 magnification (see MATERIALS and
METHODS). Each micrographs shown in A and B represents 350
mm in width. C and D) PIAS 2, 3 and 4 may not be regulated
during TGFb-induced EMT. C) Transcript levels of PIAS family
members in NMuMG cells may not be affected by TGFb-induced
EMT. RNA extracts from NMuMG cells that were left untreated
or were incubated with TGFb for 48 h, were subjected to reverse
transcription followed by PCR amplification (RT-PCR) using
specific primers for mouse PIAS1, PIAS2, PIAS3, PIAS4 and
GAPDH, with the latter serving as internal control (see Material
and Methods S1 for details). For each PIAS family member, 1 ng
of an expression plasmid containing cDNA encoding the
respective PIAS member was also subjected to PCR as a positive
control (PCR). D) Determination of protein levels of PIAS2,
PIAS3 and PIAS4 in NMuMG cells during EMT. Lysates of
NMuMG cells left untreated or treated with TGFb for 48 h, were
immunoblotted for PIAS2, PIAS3 and PIAS4 and actin, the latter
to serve as a loading control. Lysates of 293T cells transfected with
control vector (2) or one expressing PIAS2, PIAS3 or PIAS4 (+)
were subjected to the respective PIAS antibody immunoblotting as
positive controls.
Found at: doi:10.1371/journal.pone.0013971.s002 (5.05 MB TIF)
Figure S2 Quantitative analysis of PIAS1 levels in transiently
transfected NMuMG cells. Ai) NMuMG cells transiently co-
transfected with a GFP-expressing plasmid together with the
control vector (2), or one encoding wild type (WT) or SUMO E3
ligase mutant (CS) PIAS1 cDNA were subjected to indirect
immunofluorescence using an anti-PIAS1 antibody as primary
antibody followed by incubations with Cy3-conjugated antibody,
as the secondary antibody, and Hoechst 33342 nuclear stain. Cells
were visualized using fluorescence microscopy for endogenous (2)
or exogenous (WT or CS) PIAS1 (red), GFP (green) and nuclei
(blue). Arrows indicate transfected cells as determined by GFP
expression. Representative images of an experiment that was
repeated five times show equivalent localization and expression of
the wild type and SUMO E3 ligase mutant PIAS1 in transfected
NMuMG cells. Aii) Transfected cells, as determined by GFP
expression shown in Ai, were subjected to quantitative analysis of
the intensity of the PIAS1 immunofluorescence signal (see
Materials and Methods S1). Bi) Knockdown of endogenous PIAS1
in NMuMG cells by PIAS1 RNAi. NMuMG cells were transiently
transfected with a control RNAi vector or one encoding a PIAS1
short hairpin RNA. Both RNAi vectors also co-expressed GFP.
Cells were subjected to indirect anti-PIAS1 immunofluorescence
and Hoechst 33342 nuclear staining, as in Ai, and were visualized
using fluorescence microscopy for endogenous PIAS1 (red), GFP
(green) and nuclei (blue). Scans are representative images from an
experiment that was repeated four independent times. Arrows
indicate transfected cells, as determined by GFP expression. Bii)
Transfected cells, as determined by GFP expression shown in Bi,
were subjected to quantitative analysis of the intensity of the
PIAS1 immunofluorescence signal (see Materials and Methods S1
for details). Data show that PIAS1i is effective in reducing
endogenous PIAS1 levels. Each column in graph shown in Aii and
Bii represents the mean (6 SEM) of the average PIAS1 intensity
per cell from five and four independent experiments, respectively,
expressed relative to the respective control. * indicates significant
differences (P, 0.5) from the control.
Found at: doi:10.1371/journal.pone.0013971.s003 (26.78 MB
TIF)
Figure S3 PIAS1 suppresses the ability of TGFb to induce actin
reorganization and cell morphology change. A) Control vector
(2), wild type PIAS1 (WT), or SUMO E3 ligase mutant PIAS1
(CS) expressing cells that were left untreated (I) or incubated with
20 pM (II) or 100 pM (III) TGFb for 48 h were subjected to actin
and nuclear fluorescent co-staining (see MATERIALS and
METHODS). Wild type but not the SUMO E3 ligase mutant
PIAS1 suppresses the ability of TGFb to induce actin reorgani-
zation. B) Cells treated as in A, were costained with the whole cell
fluorescent dye CMFDA and Hoechst 33342 nuclear stain (see
MATERIALS and METHODS). Fluorescent images were
captured as described in Figure S1. PIAS1 acts in a SUMO ligase
dependent manner to reduce the ability of TGFb to induce
fibroblastic cell shape change associated with EMT.
Found at: doi:10.1371/journal.pone.0013971.s004 (4.69 MB TIF)
Figure S4 Quantitative analysis of transiently expressed PIAS1
and SnoN levels in NMuMG cells. Ai) NMuMG cells stably
expressing wild type SnoN (WT) or SUMO loss of function SnoN
(EdA), or stably transfected with the vector control (2) were
transiently transfected with a GFP-expressing plasmid together
with an empty expression vector control (2), or one expressing the
PIAS1 protein were subjected to indirect immunofluorescence
using an anti-PIAS1 antibody as primary antibody followed by
incubations with Cy3-conjugated antibody, as the secondary
antibody, and Hoechst 33342 nuclear stain. Cells were visualized
using fluorescence microscopy for endogenous (2) or exogenous
PIAS1 (red), GFP (green) and nuclei (blue). Representative images
of an experiment that was repeated four times show equivalent
expression of exogenous PIAS1 in different stable NMuMG cells.
Aii) Transfected cells, as determined by GFP expression shown in
Ai, were subjected to quantitative analysis of the intensity of the
PIAS1 immunofluorescence signal (see Materials and Methods S1
for details). Each column in the graph represents the mean (6
SEM, n= 4 independent experiments) of the average exogenous
PIAS1 intensity per cell of a stable transfectant expressed relative
to its respective empty expression vector control. Bi) NMuMG
cells stably expressing wild type PIAS1 (WT) or SUMO E3 ligase
mutant PIAS1 (CS) or stably transfected with the vector control
(2) were transiently transfected with a GFP-expressing plasmid
together with an empty expression vector control (2), or one
expressing SnoN protein were subjected to indirect immunoflu-
orescence using an anti-SnoN antibody as primary antibody
followed by incubations with Cy3-conjugated antibody, as the
secondary antibody, and Hoechst 33342 nuclear stain. Cells were
visualized using fluorescence microscopy for endogenous (2)o r
exogenous SnoN (red), GFP (green) and nuclei (blue). Represen-
PIAS1 Negatively Regulates EMT
PLoS ONE | www.plosone.org 13 November 2010 | Volume 5 | Issue 11 | e13971tative images of an experiment that was repeated four times show
equivalent expression of exogenous SnoN in different stable
NMuMG cells. Aii) Transfected cells, as determined by GFP
expression shown in Ai, were subjected to quantitative analysis of
the intensity of the SnoN immunofluorescence signal (see
Materials and Methods S1 for details). Each column in the graph
represents the mean (6 SEM, n= 4 independent experiments) of
the average exogenous SnoN intensity per cell of a stable
transfectant expressed relative to its respective empty expression
vector control.
Found at: doi:10.1371/journal.pone.0013971.s005 (14.20 MB
TIF)
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